알림
뒤로

Global Open

Innovation

Challenge



with

We're searching the globe for the most innovative biotech startups ready to shape the future of medicine — in partnership with CELLTRION, one of Asia's leading biopharmaceutical companies.

Global Applications      Top 5 Companies Selected        Prize & Partnership

BIOCHINA 2026 · SUZHOU
Bridging Bio Excellence: Suzhou & Incheon
Global Open Innovation Challenge in Partnership with CELLTRION
TBZ Partners presented and promoted the Green Ticket program at BIOCHINA 2026, connecting global biotech innovators with CELLTRION's open innovation ecosystem.


with 

We're searching the globe for the most innovative biotech startups ready to shape the future of medicine — in partnership with CELLTRION, one of Asia's leading biopharmaceutical companies.

    Global Applications

  Top 5 Companies Selected

    Prize & Partnership

BIOCHINA 2026 · SUZHOU
Bridging Bio Excellence: Suzhou & Incheon
Global Open Innovation Challenge in Partnership with CELLTRION
TBZ Partners presented and promoted the Green Ticket program at BIOCHINA 2026, connecting global biotech innovators with CELLTRION's open innovation ecosystem.

ABOUT THE PROGRAM

What is the Green Ticket?

A first-of-its-kind open innovation program co-organized by Incheon Metropolitan City, Incheon Technopark, CELLTRION, and TBZ Partners — bringing world-class biotech startups directly into the CELLTRION innovation ecosystem.


Global Scouting


We search worldwide for innovative biotech, digital health, and drug delivery startups aligned with CELLTRION's R&D roadmap and strategic priorities.


PoC Collaboration


Top 5 selected companies enter a structured Proof of Concept collaboration directly with CELLTRION's research and business teams.


Final Partnership


3 finalists pitch at Korea's premier Pharma-Bio Investment Convention and compete for prizes, global deals, and long-term partnership opportunities.

10
Shortlisted
Companies

Stage 1 · Document Screening


->
PITCH		5

PoC
Partners

Stage 2 · Pitch Evaluation


->
POC
3
Final
Winners

🏆 Demo Day · Dec 2026


Areas of Interest

CELLTRION's Technology Focus

CELLTRION is actively seeking partnerships across four strategic technology domains that align with its long-term R&D pipeline and innovation roadmap.

01 NOVEL ANTIBODY & AI PLATFORM




  • Novel Antibody Technologies

    ▪ Bispecific / Multispecific Antibodies (BsAb / MsAb)

    - Immune Cell Engagers

    - Conditional Activation Platforms

    ▪ Antibody Conjugates

    - Degrader Antibody Conjugates (DAC)

    - Dual Payload Platform

    - Novel Linker-Payload Platform

    - Antibody-Oligonucleotide Conjugates (AOC)

    - Antibody Radionuclide Conjugates (ARC)


    AI-Enabled Antibody Discovery & Developability

    ▪ Antibody Discovery Platform

    ▪ AI-based Antibody Developability Assessment  (In silico Antibody Developability Test)

02 DRUG DELIVERY & TRANSLATIONAL MODELS




  • Targeted & Organ-Specific Drug Delivery Systems (DDS)

    ▪ Organ-Specific Drug Delivery Platforms

    - Large Intestine-Specific Drug Delivery Technologies

    - Class IV Medical Device-Based Transdermal Drug Delivery

    ▪ Advanced Pharmaceutical Manufacturing

    - 3D Printing-Based Pharmaceutical Manufacturing Platform

    ▪ Alternative Administration & Extended Release Systems

    - Long-acting Injectable Formulations (3–6 months duration)

    - Oral Replacement Platforms for Injectable Drugs


    Translational Research & Advanced Models

    ▪ Patient-Derived Organoids (PDO)

    ▪ New Approach Methodologies (NAMs) (Animal Testing Alternatives)



03 PEPTIDES & NEW MODALITIES




  • Peptide-Based Therapeutics
  • ▪ Peptide Conjugate & Radiotherapeutics
    - Peptide Drug Conjugates (PDC)
    - Peptide Radionuclide Therapy (PRT)
    ▪ Peptide Screening Platforms
    - High-Throughput Screening (HTS)
    - Phage Display
    - mRNA Display
    ▪ Targeted Therapeutics
    - GLP-1-based Metabolic Disease Therapies (Obesity, Type 2 Diabetes, MASH)
    - Muscle Homeostasis Modulators (Sarcopenia, Cachexia)

    New Modalities
    ▪ Anti-aging Therapeutics
    ▪ Cell & Gene Therapy (CGT)
    ▪ Injectable Medical Device Grade IV Materials (PN / PLA)
    ▪ Microbiome Therapeutics
    ▪ Live Biotherapeutic Products (LBP)

04 MANUFACTURING & FORMULATION




  • Cell Line Development (CLD)

    ▪ High-expression and High-stability Vector Systems & Components

    ▪ Multi-antibody Expression Optimization Systems

    ▪ Omics-based CLD Optimization

    ▪ Targeted Integration-based Next-generation Cell Line Development

    ▪ Cell-free Manufacturing Systems 

     

    Advanced Formulation & Drug Product Development

    ▪ Development of Novel Excipients

    ▪ High-concentration Liquid Formulation Design for Antibody / ADC

    ▪ Microsphere Technologies for Antibody / ADC










ABOUT THE PROGRAM

What is the Green Ticket?

A first-of-its-kind open innovation program co-organized by Incheon Metropolitan City, Incheon Technopark, CELLTRION, and TBZ Partners — bringing world-class biotech startups directly into the CELLTRION innovation ecosystem.


Global Scouting


We search worldwide for innovative biotech, digital health, and drug delivery startups aligned with CELLTRION's R&D roadmap and strategic priorities.


PoC Collaboration


Top 5 selected companies enter a structured Proof of Concept collaboration directly with CELLTRION's research and business teams.


Final Partnership


3 finalists pitch at Korea's premier Pharma-Bio Investment Convention and compete for prizes, global deals, and long-term partnership opportunities.

Areas of Interest

CELLTRION's Technology Focus

CELLTRION is actively seeking partnerships across four strategic technology domains that align with its long-term R&D pipeline and innovation roadmap.

01

NOVEL ANTIBODY & AI PLATFORM

Novel Antibody Technologies

  • Bispecific / Multispecific Antibodies (BsAb / MsAb)
  • Immune Cell Engagers
  • Conditional Activation Platforms
  • Antibody Conjugates
  • Degrader Antibody Conjugates (DAC)
  • Dual Payload Platform
  • Novel Linker-Payload Platform
  • Antibody-Oligonucleotide Conjugates (AOC)
  • Antibody Radionuclide Conjugates (ARC)

AI-Enabled Antibody Discovery & Developability

  • Antibody Discovery Platform
  • AI-based Antibody Developability Assessment (In silico Antibody Developability Test)
02

DRUG DELIVERY & TRANSLATIONAL MODELS

Targeted & Organ-Specific Drug Delivery Systems (DDS)

  • Organ-Specific Drug Delivery Platforms
  • Large Intestine-Specific Drug Delivery Technologies
  • Class IV Medical Device-Based Transdermal Drug Delivery
  • Advanced Pharmaceutical Manufacturing
  • 3D Printing-Based Pharmaceutical Manufacturing Platform
  • Alternative Administration & Extended Release Systems
  • Long-acting Injectable Formulations (3-6 months duration)
  • Oral Replacement Platforms for Injectable Drugs

Translational Research & Advanced Models

  • Patient-Derived Organoids (PDO)
  • New Approach Methodologies (NAMs) (Animal Testing Alternatives)
03

PEPTIDES & NEW MODALITIES

Peptide-Based Therapeutics

  • Peptide Conjugate & Radiotherapeutics
  • Peptide Drug Conjugates (PDC)
  • Peptide Radionuclide Therapy (PRT)
  • Peptide Screening Platforms
  • High-Throughput Screening (HTS)
  • Phage Display
  • mRNA Display
  • Targeted Therapeutics
  • GLP-1-based Metabolic Disease Therapies (Obesity, Type 2 Diabetes, MASH)
  • Muscle Homeostasis Modulators (Sarcopenia, Cachexia)

New Modalities

  • Anti-aging Therapeutics
  • Cell & Gene Therapy (CGT)
  • Injectable Medical Device Grade IV Materials (PN / PLA)
  • Microbiome Therapeutics
  • Live Biotherapeutic Products (LBP)
04

MANUFACTURING & FORMULATION

Cell Line Development (CLD)

  • High-expression and High-stability Vector Systems & Components
  • Multi-antibody Expression Optimization Systems
  • Omics-based CLD Optimization
  • Targeted Integration-based Next-generation Cell Line Development
  • Cell-free Manufacturing Systems

Advanced Formulation & Drug Product Development

  • Development of Novel Excipients
  • High-concentration Liquid Formulation Design for Antibody / ADC
  • Microsphere Technologies for Antibody / ADC

The Application Process

How We Select Partners

01
MAR – MAY 2026

Submit Application

Complete the online application form with your company profile, technology overview, IR deck, and fundraising information.

02
JUN – JUL 2026

Shortlist & Pitch

A subset of applications will be identified as finalists by the selection committee.

03
AUG – OCT 2026

PoC Collaboration

Top 5 selected companies run a structured PoC program directly.

04
DEC 2026 🏆

Final Demo Day & Awards

All 5 finalists pitch live — 3 companies selected.

STAGE 1 JUN - JUL

DOCUMENT SCREENING  - TOP 10 COMPANIES

STAGE 2 · Jul

Pitch Evaluation  - Top 5 PoC Partners

The Application Process

How We Select Partners

01

Mar – May 2026


Submit Application


Complete the online application form with your company profile, technology overview, IR deck, and fundraising information.

02

Jun – Jul 2026


Shortlist & Pitch


A subset of applications will be identified as finalists by the selection committee. Top 10 companies will be invited to pitch.

03

Aug – Oct 2026


PoC Collaboration


Top 5 selected companies run a structured PoC program directly with CELLTRION. KPI-based milestones verified throughout.

04

Dec 2026 🏆


Final Demo Day & Awards


All 5 finalists pitch live at the Pharma-Bio Investment Convention in Incheon — 3 companies are selected as winners and awarded prizes.

STAGE 1 JUN - JUL 

DOCUMENT SCREENING  

- TOP 10 COMPANIES

STAGE 2 · Jul

Pitch Evaluation  

- Top 5 PoC Partners

For Top 5 Companies

PoC Collaboration Program

CELLTRION and the 5 selected companies run a structured PoC program. All processes are standardized on a SaaS-based PM platform.

STEP 01 · BUILD

Collaboration Model (5 Companies)

  • Strategic advisory: define collaboration direction from technology & business perspective
  • PoC / Pilot support: set project goals, KPIs, milestones and manage execution
  • Results-focused management: assess data-driven collaboration feasibility & next steps
STEP 02 · EXECUTE

Type-based PoC Validation

Platform Technology Company

Apply CELLTRION's lead compound to startup's platform → test → decide internal joint research based on results

Drug Substance Company

Secure initial substance efficacy/safety data → set KPIs → advance additional verification & joint research

STEP 03 · SELECT

Final Shortlist (3 Companies)

  • Technology synthesis: rigorous assessment of research output quality & reproducibility
  • Research collaboration discussion: select top 3 based on comprehensive evaluation
  • Follow-up roadmap: deliver final report & proposal linked to CELLTRION's program

For Top 5 Companies

PoC Collaboration Program

CELLTRION and the 5 selected companies run a structured PoC program. All processes are standardized on a SaaS-based PM platform.

STEP 01 · BUILD
Collaboration Model (5 Companies)
  • Strategic advisory: define collaboration direction from technology & business perspective
  • PoC / Pilot support: set project goals, KPIs, milestones and manage execution
  • Results-focused management: assess data-driven collaboration feasibility & next steps
STEP 02 · EXECUTE
Type-based PoC Validation
Platform Technology Company

Apply CELLTRION's lead compound to startup's platform → test → decide internal joint research based on results

Drug Substance Company

Secure initial substance efficacy/safety data → set KPIs → advance additional verification & joint research

STEP 03 · SELECT
Final Shortlist (3 Companies)
  • Technology synthesis: rigorous assessment of research output quality & reproducibility
  • Research collaboration discussion: select top 3 based on comprehensive evaluation
  • Follow-up roadmap: deliver final report & proposal linked to CELLTRION's program

For Final 3 Companies

What You Win

All five finalists will have the opportunity to pitch in Korea at the nation’s premier pharma-bio investment event.


Pharma-Bio Investment Convention '26


Pitch live in front of Korea's top pharma investors, VCs, and CELLTRION executives at Korea's largest bio-pharma investment event — hosted by Incheon Technopark in December 2026, Incheon.














   Incheon Landing Package

Move-in space, incubation program & public funding linkage reviewed for top companies — supporting settlement within the Incheon Bio Cluster


   CELLTRION Follow-up Program

3 confirmed collaboration candidates enter CELLTRION's own internal follow-up program — joint research, technology licensing & investment cooperation pursued on an ongoing basis

   Investor Network Access

Deep-dive investment meetings with domestic & global AC/VCs and strategic partners

   AC Program — Joint Education & Networking
Common education sessions & networking day operated for all selected companies to accelerate collaboration readiness

APPLY NOW

Applications open
Mar – May 2026.

Submit your application now. The program kicks off in March 2026 

— early applicants are reviewed on a rolling basis.

    Open call: March – May 2026


   All information kept strictly confidential


   Open to companies worldwide


Questions? Contact via WeChat

WeChat ID: wxid_wm8n1okflhpt22

작성

© 2026 TBZ Partners. All rights reserved. · Global Open Innovation Challenge with CELLTRION